



Covid-19: Review on Worldwide Pandemic Outbreak

Bhawanpreet Kaur¹, Atinderjit Singh², Nitu Trehan³

¹Guru Angad Dev Veterinary and Animal Science University (GADVASU), Ludhiana

²Department of Dairy Science, Mata Gujri College, Fatehgarh sahib

³Department of Biotechnology, Mata Gujri College, Fatehgarh sahib

Author for Correspondence: Email-bhawanpreet01@gmail.com

Received: 20 October 2020/Accepted: 25 November 2020

URL: <https://doi.org/10.38112/agw.2020.v08i02.004>

Abstract Coronavirus are largest group of non-segmented, enveloped, zoonotic RNA viruses, characterised by crown-like spikes that project from their surface. Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are highly pathogenic coronavirus. It infects humans, non-humans and cause variety of diseases. CoVs mostly cause respiratory and gastrointestinal diseases from the common cold to more severe. Transmission may be symptomatic and asymptomatic. Human to human is the main driver of spreading COVID-19 infection. Various strategies are underworking to develop anti-drug or vaccines against COVID-19 pandemic. Different mitigation measures have been used to fight against (COVID-19).

Keywords: Disease, SARS, RNA, pandemic.

Introduction

Orthocoronavirinae or Coronavirinae is the scientific name of coronavirus. A novel Coronaviruses (COVID-19) are wide a group of viruses belong to the family Coronaviridae, order Nidovirales. Four different genera of CoVs, namely, Alphacoronavirus (?CoV), Betacoronavirus (?CoV), Deltacoronavirus (?CoV), and Gammacoronavirus (?CoV). The crown-like appearance of the viral particle due to the presence of spike glycoproteins on the envelope from which they were named after. Most of the deadly infectious diseases are infected by the viruses. COVIDs are single stranded, non-segmented, enveloped RNA viruses known to be responsible for a broad spectrum of diseases in various species. They infect a wide range of animals including cattle, horses, camels, cats, dogs, rodents, birds, bats, pigs, horses, whales, and humans. The coronavirus affecting the human population is referred to as human coronavirus (HCoVs).

It is considered a zoonotic virus. Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012. The SARS-CoV-2 is 2019 novel coronavirus that currently causing a severe outbreak of disease termed as COVID-19 in China and many other countries, threatening to cause a global pandemic.

Structure of Coronavirus

The SARS-CoV is a betacoronavirus. It contains four major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) (Snijder et al., 2003). The S, M, and E proteins together form the envelope of the virus. The presence of M protein is the most abundant and it is responsible for the shape of the envelope. The E protein is the smallest structural protein. The RNA also serves as a template for in vitro translation of viral proteins (Leibowitz et al., 1982). The number of accessory proteins and their function is unique depending on the specific coronavirus (Fehr et al., 2015). The envelope glycoproteins are responsible for attachment to the host cell.




Figure 1 Structure of coronavirus

Genome Organisation

The genome of coronavirus is linear with positive-sense single-stranded RNA (+ssRNA) virus that has icosahedral nucleocapsids and replicate in the cytoplasm of host cell. Usually, the genome of RNA viruses is less than 10 kb length with 38% G + C content. Coronavirus genome size from 28-32 kb, (Lee et al., 1991) the largest among RNA viruses. The genome is polyadenylated at the 3' end and predicted to have 14 functional open reading frames (ORFs) (Rota et al., 2003). In terms of Whole genome sequence (WGS), SARS-CoV-2 is closer to the SARS-like bat coronavirus. Mutations are observed in NSP2 and NSP3 and the spike protein, that plays a great role in infectious capability and differentiation mechanism of SARS-CoV-2

The envelope glycoproteins are responsible for attachment to the host cell. Coronaviruses are divided into three serotypes: groups 1, group 2, and group 3 (Enjuanes et al., 2000). Group 2 coronaviruses contain a gene encoding hemagglutinin esterase (HE) that is homologous to the influenza C virus.

Types of Coronavirus

Based on symptoms, human coronavirus (HCoV) is classified into two different strains. The common human coronavirus produces mild symptoms and rare coronavirus infection produce potentially severe symptoms.

Human coronaviruses produce mild symptoms

1. Human coronavirus 229E, alpha coronavirus (?-CoV)
2. Human coronavirus NL63, alpha coronavirus (?-CoV)
3. Human coronavirus OC43, beta coronavirus (?-CoV)
4. Human coronavirus HKU1, beta coronavirus (?-CoV)

Human Coronaviruses Produce Severe Symptoms

1. Middle East respiratory syndrome-related coronavirus (MERS-CoV), beta coronavirus (?-CoV)
2. Severe acute respiratory syndrome coronavirus (SARS-CoV), beta coronavirus (?-CoV)
3. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), beta coronavirus (?-CoV)

Symptomatic Transmission

The transmission of COVID-19 viral infection from a person who have signs or symptoms development.

Asymptomatic Transmission

The transmission of COVID-19 viral infection from a person who doesn't develop any signs or symptoms. The recent reported cases are truly asymptomatic.

Common Symptoms

After a coronavirus infection, the onset of symptoms takes 2-4 days or sometimes more. The most common symptoms of COVID-19 which leads from the minor infectious diseases to lethal effects.

1. Direct contact or Close contact
2. Contaminated surfaces or objects
3. Respiratory droplets
4. Cough
5. Watery diarrhoea
6. Sneezing
7. Breathlessness
8. Headache
9. Fever
10. Sore throat

Risk Assessment of Covid-19 Illness

- Covid-19 increase with increase in population age (People who are older have a higher risk of infection)
- Weakened immune system
- High blood pressure
- Type-2 Diabetes
- Pregnancy
- Cardiovascular disease
- Asthma
- Kidney disease & Lung disease

Life Cycle of Corona Virus

1. Attachment and entry into cell
2. Replicase protein expression
3. Replication and transcription
4. Assembly and release




Figure 2 Life cycle of coronavirus

Route of Transmission

According to the CDC (Centre for Disease Control and Prevention), the complications are more common in the lower respiratory tract. Symptomatic people are the most common source of COVID-19 spread and remain asymptomatic people transmit the virus isolation is the best way to contain the epidemic. The new coronavirus has been responsible for millions of infections globally, causing hundreds of thousands of deaths. Basically COVID-19 virus is transmitted between people via respiratory droplets and contact routes (Liu et al., 2020). Droplet transmission is commonly occurring when a person comes in close contact with the person who has respiratory symptoms. Transmission may also occur through fomites in the immediate environment around the infected person. (ong et al., 2020). Initially, the outbreak began in china, coronavirus has been identified as a cause of large disease from bat origin (Zhu et al., 2020) and (Drosten et al. 2003). During pregnancy the possibility of transmission COVID-19 between mothers and infants (Chen et al., 2020). SARS-CoV has a higher degree of stability in the environment than other known human coronaviruses (Rabenau et al., 2005). Human-to-human transmission is the only plausible explanation for the magnitude of the on-going outbreak. (Imai et al., 2020). SARS-CoV primarily infects epithelial cells within the lung. The virus can enter macrophages and dendritic cells but only leads to an abortive infection. Sputum and saliva contain large amount of this virus. Coronaviruses are capable of adapting new environments through mutation and recombination.

Epidemiology

In 2012, Saudi Arabia was infected with coronavirus belongs to beta-coronavirus originating from camels as a primary host (Paden et al., 2018). The COVID-19 was first reported from the Wuhan, Hubei Province in the People's Republic of China as the cause of respiratory illness in December 2019, have rapidly assumed a global form (Kim et al., 2020). Human coronavirus (HCoVs) poses a major threat to global public health. At the beginning of the outbreak, china was reported as higher mortality rate. Before the coronavirus outbreak, Nipah virus and Hendra virus are two zoonotic coronaviruses were originated from bats in Asia and Africa. (Halpin et al., 2000 and Yob et al., 2001) As of February 28, 2020, there have been 83,704 confirmed cases of COVID-19 globally, with 2,859 deaths by WHO. Wuhan, the centre of the epidemic with 10 million population, is also an important centre in the spring festival transportation network. In March the World

Health Organization (WHO) declared the outbreak a pandemic.

Table 1: The most affected to least affected country, number of cases and death of COVID - 19 outbreaks, according to Worldometer reports on July 5, 2020.

Countries	Cases	Deaths
United states of America	2,957,291	132,413
India	695,396	19,692
Germany	197,460	9,085
Canada	105,317	8,674
China	83,553	4,634
Australia	8,449	104
Hongkong	1,269	7
Taiwan	449	7

Prevention

Careful monitoring of COVID-19 by sterilised hospitals. High risk of nosocomial spread (Wang et al., 2019). Strategies and standard preventative measures imply to prevent the transmission of diseases.

- Hygiene, physical or social distancing, wearing mask reduce the rate of transmission.
- Using personal protective equipment (PPE) and washing hands is recommended best to prevent the spread of infection.
- CDC (Centre for Disease Control and Prevention) recommended using an alcohol-based hand sanitizer with at least 60% alcohol by volume when soap and water are not readily available.
- Surface cleaners are used to decontaminate the force of infection.
- Testing, quarantine and self-isolation are encouraged to reduce the rate of virus spread. Public gatherings should be avoided.
- Increasing health literacy in the population can improve the management and control of COVID-19 and even further global pandemics.

Vaccination

Different strategies are used to develop a vaccine against SARS-CoV can be effective. There is no available vaccine against COVID-19. To date, there are no anti-viral therapeutics that specifically target human coronaviruses, so treatments are only supportive. Despite this, several strategies are being developed for vaccine development for live-attenuated vaccines for instance by making gene rearrangements and knockouts in the nsp1 (Zust et al., 2007) or E proteins rearranging the 3' end of the genome

(De han et al., 2002) modifying the TRS sequences , or using mutant viruses with abnormally high mutation rates that significantly attenuate the virus (Graham et al., 2005). Cross-reactivities between antibodies against SARS-CoV and common CoVs have been observed (Che et al., 2005). CDC (Centre for Disease Control and Prevention) works on the development of an inactivated virus vaccine.

Diagnosis and Treatment

- The two commonly known Reverse real-time quantitative polymerase chain reaction (RT-qPCR) and high-throughput sequencing are the two nucleic acid detection technologies for SARS-CoV-2 (Lippi et al., 2005).
- Chest X-ray examination has low sensitivity of early diagnosis in lung changes.
- High resolution chest computed tomography (CT) used in detection of Covid-19 pneumonia. symptomatic, -immunoglobulin and respiratory treatment is necessary.

Conclusion

SARS-CoV-2 is a betacoronavirus is a zoonotic viral agent. bats seem to be a significant reservoir for these viruses. It is easily transmitted from animals to humans and cause severe disease. However, the researchers are working to develop efficient strategies to cope with the infection.

References

- Che XY, Qiu LW, Liao ZY, Wang YD, Wen K, Pan YX, Hao W, Mei YB, Cheng VCC, Yuen KY .2005. Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. *Journal of Infectious Diseases* 191:2033-2037.
- Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J , Zhao D ,Xu D, Gong Q, Liao J, Yang J, Hou Y W , Zhang Y. 2020. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records, *The Lancet*. 395: 809-815
- De Han CA, Volders H, Koetzner CA, Masters PS, Peter JM, Rottier PJM. 2002. Coronaviruses maintain viability despite dramatic rearrangements of the strictly conserved genome organization. *Journal of Virology* 76:12491-12502.
- Drosten C, Gunther S, Preiser W, vander Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RAM., et al. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *New England Journal of Medicine*. 348:1967-1976. doi: 10.1056/NEJMoa030747.
- Fehr AR, Perlman S. 2015. "Coronaviruses: an overview of their replication and pathogenesis". In Maier HJ, Bickerton E, Britton P (eds.). *Coronaviruses. Methods in Molecular Biology*. Springer 1282:1-23.
- Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baricet RS. 2012. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. *Nature Medicine*.18:1820-1826.
- Halpin K, Young PL, Field HE, Mackenzie JS. 2000. Isolation of Hendra virus from pteropid bats: A natural reservoir of Hendra virus. *Journal of Virology*. 81:1927-32. 47.
- Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, et al. Report 3: Transmissibility of 2019-nCoV.2020. Available from: <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-transmissibility-25-01-2020.pdf>,
- Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, Park JH, Na HK, and Oh MD. 2020.The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: Implication for infection prevention and control measures. *Journal of Korean Medical Science*. 35: e61.
- Lee HJ, Shieh CK, Gorbalenya AE, Koonin EV, La Monica N, Tuler J, Bagdzhadzhyan A, Lai MM.1991. The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding theputative proteases and RNA polymerase. *Virology*.180(2):567-82.
- Leibowitz JL, Weiss SR, Paavola E, Bond CW. 1982. Cell-free translation of murine coronavirus RNA. *Journal of Virology*. 43:905-913
- Lippi G, Simundic AM, Plebani M. 2020. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clinical Chemistry and Laboratory Medicine*. doi: 10.1515/cclm-2020-0285
- Enjuanes L, Brian D, Cavanagh D, Holmes K, Lai MMC, Laude H, Masters P, Rottier P, Siddell S, Spaan WJM, Taguchi F, Talbot P, Coronaviridae, in: van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeoch DJ, Pringle CR, Wickner RB (Eds.) 2000. *Virus Taxonomy, Classification and Nomenclature of Viruses*, Academic Press.New York pp 835-849.
- Liu J, Liao X, Qian S, Yuan J, Wang F, Liu Y, Wang Z, Wang FS, Liu L and Zhang Z. 2020. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, *Emerging Infectious Diseases*. 26: doi.org/10.3201/eid2606.200239

- Ong SW, Tan YK, Chia PY, Lee TH, Ng OT, Wong MS, Marimuthu K. 2020. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. *JAMA*. 323(16):1610-1612
- Paden C, Yusof M, Al Hammadi Z, Queen K, Tao Y, Eltahir Y, Elsayed E, Marzoug B, Bensalah OK, Khalafalla A, Al Mulla M, Khudhair A, Elkheir K, Issa Z, Pradeep K, Elsaleh F, Imambaccus H, Sasse J, Weber S, Shi M, Zhang J, Li Y, Pham H, Kim L, Hall A, I Gerber S, Al Hosani F, Tong S, Al Muhairi S. 2018. Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE. *Zoonosis Public Health*. 65(3):322-333 doi: 10.1111/zph.12435
- Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W and Doerr HW. 2005. Stability and inactivation of SARS coronavirus. *Medical Microbiology and Immunology*. 194(1-2):1-6
- Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnol R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez PA, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, and Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. *Science*. 300:1394-1399
- Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LL, Guan Y, Rozanov M, Spaan WJ, Gorbalenya A. 2003. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2. *Journal of Molecular Biology*. 331(5): 991-1004
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang W and Peng Z. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 323:1061-1069.
- World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report - 39. Geneva: WHO; 2020.
- Yob JM, Field H, Rashdi AM, Morrissy C, van der Heide B, Rota P, Adzhar A, White J, Daniels P, Jamaluddin A, Ksiazek A. 2001. Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. *Emerging Infectious Disease*. 7(3):439-441.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Xuejun M, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. China Novel Coronavirus Investigating and Research Team. 2019. A novel coronavirus from patients with pneumonia in China. *New England Journal of Medicine*. 382(8):727-733. doi:10.1056/NEJMoa2001017
- Zust R, Cervantes-Barragan L, Kuri T, Blakqori I, Weber F, Ludewig B, Thiel V. 2007. Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines. *PLoS Pathogens*. 3(8):109-112.